Explanatory Note:
This Amendment No. 1 (“Amendment”) amends and supplements the Schedule 13D originally filed by the Reporting Entities with Securities and Exchange Commission on October 1, 2020 (the “Original Schedule 13D”). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13D remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment have the meanings ascribed to them in the Original Schedule 13D.
Item 1. Security and Issuer.
The address of the principal executive offices of the Issuer is 1560 Trapelo Road, Waltham, Massachusetts 02451. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable
Item 4. Purpose of Transaction.
Solely on behalf of, and only to the extent that it relates to, the Reporting Entities, Item 4 of the Original Schedule 13D is hereby amended and supplemented by the addition of the following:
The Reporting Entities have previously reserved the right and continue to reserve the right, based on all relevant factors and subject to applicable law or other restrictions, at any time and from time to time, to acquire additional shares of Common Stock or other securities of the Issuer, dispose of some or all of the shares of Common Stock or other securities of the Issuer that it may own from time to time, in each case in open market or private transactions, block sales or otherwise or pursuant to ordinary stock exchange transactions effected through one or more broker-dealers whether individually or utilizing specific pricing or other instructions (including by means of Rule 10b5-1 programs), and review or reconsider their position, change their purpose, take other actions or formulate and implement plans or proposals with respect to any of the foregoing.
The Reporting Entities intend to review their investment in the Issuer from time to time on the basis of various factors, including the Issuer’s business, financial condition, results of operations and prospects, general economic and industry conditions, the securities markets in general and those for the Issuer’s stock in particular, as well as other developments.
Item 5. Interest in Securities of the Issuer.
Solely on behalf of, and only to the extent that it relates to the Reporting Entities, Item 5 of the Original Schedule 13D is hereby amended as follows:
(a) and (b) See Items 7-11 of the cover pages of this Amendment for each Reporting Entity.
(c) On August 10, 2022, Vida II sold 37,843 shares of Common Stock at a weighted average price per share of $12.0591 for aggregate proceeds of $456,352.52.
On August 10, 2022, Vida II-A sold 1,050 shares of Common Stock at a weighted average price per share of $12.0591 for aggregate proceeds of $12,662.06.
On August 11, 2022, Vida II sold 98,517 shares of Common Stock at a weighted average price per share of $12.0054 for aggregate proceeds of $1,182,735.99.
On August 11, 2022, Vida II-A sold 2,734 shares of Common Stock at a weighted average price per share of $12.0054 for aggregate proceeds of $32,822.76.
On August 12, 2022, Vida II sold 203,193 shares of Common Stock at a weighted average price per share of $12.0086 for aggregate proceeds of $2,440,063.46.
On August 12, 2022, Vida II-A sold 5,638 shares of Common Stock at a weighted average price per share of $12.0086 for aggregate proceeds of $67,704.49.
On August 15, 2022, Vida II sold 94,390 shares of Common Stock at a weighted average price per share of $11.9697 for aggregate proceeds of $1,129,819.98.
On August 15, 2022, Vida II-A sold 2,619 shares of Common Stock at a weighted average price per share of $11.9697 for aggregate proceeds of $31,348.64.
On August 16, 2022, Vida II sold 29,735 shares of Common Stock at a weighted average price per share of $11.9587 for aggregate proceeds of $355,590.51.
On August 16, 2022, Vida II-A sold 825 shares of Common Stock at a weighted average price per share of $11.9587 for aggregate proceeds of $9,865.93.
On August 17, 2022, Vida II sold 34,494 shares of Common Stock at a weighted average price per share of $11.9577 for aggregate proceeds of $412,468.90.
On August 17, 2022, Vida II-A sold 957 shares of Common Stock at a weighted average price per share of $11.9577 for aggregate proceeds of $11,443.52.
On August 18, 2022, Vida II sold 221,860 shares of Common Stock at a weighted average price per share of $11.9603 for aggregate proceeds of $2,653,512.16.
On August 18, 2022, Vida II-A sold 6,157 shares of Common Stock at a weighted average price per share of $11.9603 for aggregate proceeds of $73,639.57.
(e) Each of the Reporting Entities ceased to be a beneficial owner of more than five percent of the Issuer’s securities as of August 15, 2022.